Pharmaron Beijing Co., Ltd. (SHE:300759)
China · Delayed Price · Currency is CNY 30.26
-0.11 (-0.36%)
Jan 28, 2026, 10:05 AM CST
Pharmaron Beijing Revenue
Pharmaron Beijing had revenue of 3.64B CNY in the quarter ending September 30, 2025, with 13.44% growth. This brings the company's revenue in the last twelve months to 13.54B, up 14.83% year-over-year. In the year 2024, Pharmaron Beijing had annual revenue of 12.28B with 6.39% growth.
Revenue (ttm)
13.54B
Revenue Growth
+14.83%
P/S Ratio
3.80
Revenue / Employee
633.79K
Employees
21,370
Market Cap
51.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 12.28B | 737.78M | 6.39% |
| Dec 31, 2023 | 11.54B | 1.27B | 12.39% |
| Jan 1, 2023 | 10.27B | 2.82B | 37.92% |
| Dec 31, 2021 | 7.44B | 2.31B | 45.00% |
| Dec 31, 2020 | 5.13B | 1.38B | 36.64% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chongqing Zhifei Biological Products | 10.91B |
| Shanghai RAAS Blood Products | 7.95B |
| Beijing Tiantan Biological Products | 6.42B |
| Asymchem Laboratories (Tianjin) | 6.29B |
| Shanghai Allist Pharmaceuticals | 4.76B |
| Haisco Pharmaceutical Group | 4.27B |
| Hualan Biological Engineering | 4.27B |
| Xiamen Amoytop Biotech | 3.34B |